DermTech, which is developing non-invasive gene expression tests to diagnosis various skin conditions, withdrew its plans for an initial public offering on Thursday citing poor market conditions.
Skin-related biotech IPO Dermira (DERM) raised $125 million...read more
11 IPOs priced during the week of September 29, but only 3 had any meaningful gains, including two tech deals and American Addiction Centers, a network of substance abuse treatment centers. The group raised $2.4 billion; 25% less than expected after frac sand...read more
Dermira, a biotech targeting skin conditions such as psoriasis, excessive sweating and acne, raised $125 million by offering 7.8 million shares at $16, the high end of the range of $14 to $16. Dermira plans to list on the NASDAQ under the symbol DERM. Dermira...read more
Dermira, a biotech targeting skin conditions such as psoriasis, excessive sweating and acne, raised the proposed deal size for its upcoming IPO on Thursday. The Redwood City, CA-based company now plans to raise $117 million by offering 7.8 million shares (up...read more
Skin out of the game: DermTech withdraws $25 million IPO
DermTech, which is developing non-invasive gene expression tests to diagnosis various skin conditions, withdrew its plans for an initial public offering on Thursday citing poor market conditions. Skin-related biotech IPO Dermira (DERM) raised $125 million...read more
US IPO Pricing Recap: 11 IPOs trade poorly but investors can't get enough American Addiction
11 IPOs priced during the week of September 29, but only 3 had any meaningful gains, including two tech deals and American Addiction Centers, a network of substance abuse treatment centers. The group raised $2.4 billion; 25% less than expected after frac sand...read more
Dermira prices IPO at $16, the high end of the range
Dermira, a biotech targeting skin conditions such as psoriasis, excessive sweating and acne, raised $125 million by offering 7.8 million shares at $16, the high end of the range of $14 to $16. Dermira plans to list on the NASDAQ under the symbol DERM. Dermira...read more
Skin care biotech Dermira increases deal size 46% to $117 million
Dermira, a biotech targeting skin conditions such as psoriasis, excessive sweating and acne, raised the proposed deal size for its upcoming IPO on Thursday. The Redwood City, CA-based company now plans to raise $117 million by offering 7.8 million shares (up...read more